Fig. 1From: FXYD2 mRNA expression represents a new independent factor that affects survival of glioma patients and predicts chemosensitivity of patients to temozolomideThe expression of FXYD2 mRNA in different gender, age and recurrence status of gliomas in CGGA. The expression of FXYD2 mRNA in 516 glioma patients with different gender (A), age (B) and recurrence status (C) was compared by student’s t-test. Data represent mean ± SDBack to article page